Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD51GC)

Drug Name

LY3321367 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepatitis A virus cellular receptor 2 (TIM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MBG453	DMBPY9Z	Myelodysplastic syndrome	2A37	Phase 3	[1]
RO7121661	DM8A120	Esophageal squamous cell carcinoma	2E60.1	Phase 2	[2]
GSK4069889	DMV6SNU	Non-small-cell lung cancer	2C25	Phase 2	[3]
AZD7789	DMOIHWI	Hodgkin lymphoma	2B30	Phase 2	[4]
TB006	DMKN524	Alzheimer disease	8A20	Phase 2	[5]
BGB-A425	DMI42Q0	Non-small-cell lung cancer	2C25	Phase 1/2	[6]
LY3415244	DM5QO1A	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
Sym023	DMV3L62	Lymphoma	2A80-2A86	Phase 1	[8]
INCAGN2390	DM5SO1T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis A virus cellular receptor 2 (TIM3)	TT1RWL7	HAVR2_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
3	Clinical pipeline report, company report or official report of GlaxoSmithKline.
4	Clinical pipeline report, company report or official report of AstraZeneca
5	Clinical pipeline report, company report or official report of TrueBinding
6	Clinical pipeline report, company report or official report of BeiGene.
7	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
8	Clinical pipeline report, company report or official report of Symphogen.
9	Clinical pipeline report, company report or official report of Agenus.